Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects after Abstinence from Cannabis

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging

Volumn 1, Issue 1, 2016, Pages 60-67

  D'Souza, Deepak Cyril ^a,b,c   Cortes Briones, Jose A ^a,b,c   Ranganathan, Mohini ^a,b,c   Thurnauer, Halle ^a,b,c   Creatura, Gina ^a,b,c   Surti, Toral ^a,b,c   Planeta, Beata ^c   Neumeister, Alexander ^d   Pittman, Brian ^b,c   Normandin, Marc D ^e   Kapinos, Michael ^c   Ropchan, Jim ^c   Huang, Yiyun ^c   Carson, Richard E ^c   Skosnik, Patrick D ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b Yale University School of Medicine   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cannabinoids; Cannabis; CB1R; Dependence; Downregulation; Recovery; Tolerance; Upregulation; Withdrawal

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABIS; CARBON 11; OMAR C 11; UNCLASSIFIED DRUG;

ABSTINENCE; ADULT; ARTICLE; BRAIN REGION; CANNABIS ADDICTION; CANNABIS USE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; VOLUME OF DISTRIBUTION; WITHDRAWAL SYNDROME;

EID: 84957797131     PISSN: 24519022     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpsc.2015.09.008     Document Type: Article

References (42)

1. Substance Abuse and Mental Health Services Administration Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-48, HHS Publication No. (SMA) 14-4863 2014 Substance Abuse and Mental Health Services Administration Rockville, MD
2. Z. Mehmedic, S. Chandra, D. Slade, H. Denham, S. Foster, A.S. Patel, and et al. Potency trends of Delta9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008 J Forensic Sci 55 2010 1209 1217
3. M. Spaderna, P.H. Addy, and D.C. D'Souza Spicing things up: Synthetic cannabinoids Psychopharmacology (Berl) 228 2013 525 540
4. R. Mechoulam, L.O. Hanus, R. Pertwee, and A.C. Howlett Early phytocannabinoid chemistry to endocannabinoids and beyond Nat Rev Neurosci 15 2014 757 764
5. S. Gonzalez, M. Cebeira, and J. Fernandez-Ruiz Cannabinoid tolerance and dependence: A review of studies in laboratory animals Pharmacol Biochem Behav 81 2005 300 318
6. R.T. Jones, N.L. Benowitz, and R.I. Herning Clinical relevance of cannabis tolerance and dependence J Clin Pharmacol 21 1981 143S 152S
7. L.J. Sim-Selley Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids Crit Rev Neurobiol 15 2003 91 119
8. C.S. Breivogel, S.R. Childers, S.A. Deadwyler, R.E. Hampson, L.J. Vogt, and L.J. Sim-Selley Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain J Neurochem 73 1999 2447 2459
9. A. Oviedo, J. Glowa, and M. Herkenham Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: A quantitative autoradiographic study Brain Res 616 1993 293 302
10. L.J. Sim-Selley, N.S. Schechter, W.K. Rorrer, G.D. Dalton, J. Hernandez, B.R. Martin, and et al. Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration Mol Pharmacol 70 2006 986 996
11. D.L. McKinney, M.P. Cassidy, L.M. Collier, B.R. Martin, J.L. Wiley, D.E. Selley, and et al. Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol J Pharmacol Exp Ther 324 2008 664 673
12. J. Romero, E. Garcia-Palomero, J.G. Castro, L. Garcia-Gil, J.A. Ramos, and J.J. Fernandez-Ruiz Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions Brain Res Mol Brain Res 46 1997 100 108
13. L.J. Sim, R.E. Hampson, S.A. Deadwyler, and S.R. Childers Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain J Neurosci 16 1996 8057 8066
14. A.J. Budney, J.R. Hughes, B.A. Moore, and R. Vandrey Review of the validity and significance of cannabis withdrawal syndrome Am J Psychiatry 161 2004 1967 1977
15. A.H. Lichtman, and B.R. Martin Marijuana withdrawal syndrome in the animal model J Clin Pharmacol 42 2002 20S 27S
16. M.D. Aceto, S.M. Scates, J.A. Lowe, and B.R. Martin Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A Eur J Pharmacol 282 1995 R1 R2
17. J. Hirvonen, R.S. Goodwin, C.T. Li, G.E. Terry, S.S. Zoghbi, C. Morse, and et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers Mol Psychiatry 17 2012 642 649
18. C. Cohen, G. Perrault, C. Voltz, R. Steinberg, and P. Soubrie SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats Behav Pharmacol 13 2002 451 463
19. A. Castane, E. Valjent, C. Ledent, M. Parmentier, R. Maldonado, and O. Valverde Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence Neuropharmacology 43 2002 857 867
20. J. Ceccarini, R. Kuepper, D. Kemels, J. van Os, C. Henquet, and K. Van Laere [F]MK-9470 PET measurement of cannabinoid CB receptor availability in chronic cannabis users Addict Biol 20 2015 357 367
21. J. Hirvonen, G.E. Terry, C. Halldin, V.W. Pike, and R.B. Innis Approaches to quantify radioligands that wash out slowly from target organs Eur J Nucl Med Mol Imaging 37 2010 917 919
22. M.D. Normandin, M.Q. Zheng, K.S. Lin, N.S. Mason, R. Narendran, S.F. Lin, and et al. Imaging the cannabinoid CB1 receptor in human with [11C]OMAR: Assessment of kinetic analysis methods, test-retest reproducibility, and gender differences J Cereb Blood Flow Metab 35 2015 1313 1322
23. A.G. Horti, H. Fan, H. Kuwabara, J. Hilton, H.T. Ravert, D.P. Holt, and et al. 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors J Nucl Med 47 2006 1689 1696
24. D.C. D'Souza, W.M. Abi-Saab, S. Madonick, K. Forselius-Bielen, A. Doersch, G. Braley, and et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction Biol Psychiatry 57 2005 594 608
25. D.C. D'Souza, E. Perry, L. MacDougall, Y. Ammerman, T. Cooper, Y.T. Wu, and et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis Neuropsychopharmacology 29 2004 1558 1572
26. A.J. Budney, B.A. Moore, R.G. Vandrey, and J.R. Hughes The time course and significance of cannabis withdrawal J Abnorm Psychol 112 2003 393 402
27. E.M. Kouri, and H.G. Pope Jr Abstinence symptoms during withdrawal from chronic marijuana use Exp Clin Psychopharmacol 8 2000 483 492
28. M.A. Huestis, and E.J. Cone Differentiating new marijuana use from residual drug excretion in occasional marijuana users J Anal Toxicol 22 1998 445 454
29. R.E. Carson, W.C. Barker, J.-S. Liow, S. Adler, and C.A. Johnson Design of a motion-compensation OSEM list-mode algorithm for resolution-recovery reconstruction of the HRRT Nuclear Science Symposium Conference Record, 2003 IEEE 5 2003 3281 3285
30. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M (2002): Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. NeuroImage 15: 273-289.
31. M. Ichise, H. Toyama, R.B. Innis, and R.E. Carson Strategies to improve neuroreceptor parameter estimation by linear regression analysis J Cereb Blood Flow Metab 22 2002 1271 1281
32. D.J. Allsop, M.M. Norberg, J. Copeland, S. Fu, and A.J. Budney The Cannabis Withdrawal Scale development: Patterns and predictors of cannabis withdrawal and distress Drug Alcohol Depend 119 2011 123 129
33. J. Hirvonen, P. Zanotti-Fregonara, J.C. Umhau, D.T. George, D. Rallis-Frutos, C.H. Lyoo, and et al. Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography Mol Psychiatry 18 2013 916 921
34. E.L. Karschner, E.W. Schwilke, R.H. Lowe, W.D. Darwin, R.I. Herning, J.L. Cadet, and et al. Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers J Anal Toxicol 33 2009 469 477
35. E.L. Karschner, E.W. Schwilke, R.H. Lowe, W.D. Darwin, H.G. Pope, R. Herning, and et al. Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction 104 2009 2041 2048
36. P. Mura, P. Kintz, V. Dumestre, S. Raul, and T. Hauet THC can be detected in brain while absent in blood J Anal Toxicol 29 2005 842 843
37. G. Terry, J.S. Liow, E. Chernet, S.S. Zoghbi, L. Phebus, C.C. Felder, and et al. Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents Neuroimage 41 2008 690 698
38. C.S. Breivogel, S.M. Scates, I.O. Beletskaya, O.B. Lowery, M.D. Aceto, and B.R. Martin The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors Eur J Pharmacol 459 2003 139 150
39. D.C. D'Souza, M. Ranganathan, G. Braley, R. Gueorguieva, Z. Zimolo, T. Cooper, and et al. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis Neuropsychopharmacology 33 2008 2505 2516
40. M. Ranganathan, G. Braley, B. Pittman, T. Cooper, E. Perry, J. Krystal, and et al. The effects of cannabinoids on serum cortisol and prolactin in humans Psychopharmacology (Berl) 203 2009 737 744
41. D.C. D'Souza, D.J. Fridberg, P.D. Skosnik, A. Williams, B. Roach, N. Singh, and et al. Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Delta(9)-THC in humans Neuropsychopharmacology 37 2012 1632 1646
42. J.G. Ramaekers, G. Kauert, E.L. Theunissen, S.W. Toennes, and M.R. Moeller Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users J Psychopharmacol 23 2009 266 277